UBS Group AG - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 102 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2021. The put-call ratio across all filers is 2.57 and the average weighting 0.1%.

Quarter-by-quarter ownership
UBS Group AG ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$62,506
-27.4%
52,971
-13.2%
0.00%
Q2 2023$86,063
+1663.6%
61,037
+1776.3%
0.00%
Q1 2023$4,880
-60.3%
3,253
-69.0%
0.00%
Q4 2022$12,291
+1129.1%
10,506
+706.9%
0.00%
Q3 2022$1,000
-94.4%
1,302
-88.6%
0.00%
Q2 2022$18,000
+1700.0%
11,420
+1177.4%
0.00%
Q1 2022$1,000
-99.0%
894
-97.8%
0.00%
Q4 2021$97,000
-81.5%
39,932
-80.8%
0.00%
Q3 2021$523,000
+3923.1%
207,702
+4468.9%
0.00%
Q2 2021$13,000
-23.5%
4,546
-38.0%
0.00%
Q1 2021$17,000
-61.4%
7,337
-70.2%
0.00%
Q4 2020$44,000
+4300.0%
24,602
+2098.6%
0.00%
Q3 2020$1,0000.0%1,119
-17.5%
0.00%
Q2 2020$1,000
-98.3%
1,357
-98.1%
0.00%
Q1 2020$59,000
-57.6%
70,916
-54.5%
0.00%
Q4 2019$139,000
+69.5%
155,913
+86.6%
0.00%
Q3 2019$82,00083,5730.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q1 2021
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$41,223,8723.66%
Raffles Associates 1,587,739$1,873,5322.48%
Defender Capital, LLC. 5,184,510$6,117,7222.22%
Prescott General Partners LLC 1,851,851$2,185,1840.14%
DCF Advisers, LLC 82,751$97,6460.05%
Beirne Wealth Consulting Services, LLC 45,000$63,4500.05%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 781,766$922,4840.02%
Fort Sheridan Advisors LLC 83,931$99,0390.02%
MAI Capital Management 954,688$1,126,5320.02%
Piscataqua Savings Bank 12,499$14,6230.01%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders